Akebia Therapeutics
在场
Akebia Therapeutics 是一家在股票代码 AKBA (US) 下上市的公司。
高管
查看带有其 16 名主要高管的组织结构图
Akebia Therapeutics 搜索最多的简介
- John Butler, President and Chief Executive Officer, Director
- Michael Rogers, Director
- Myles Wolf, Director
高管在Akebia Therapeutics变化
- Erik Ostrowski已作为Senior Vice President, Chief Financial Officer and Chief Business Officer加入公司 (新闻发布的2024六月25号).
创建提醒
跟踪 Akebia Therapeutics 的高管变动
生物技术
Akebia Therapeutics 拥有 2,317 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- AgomAb Therapeutics 刚刚宣布为 89 筹款数百万美元。 (公布2024十月29号).
- Seaport Therapeutics 刚刚宣布为 225 筹款数百万美元。 (公布2024十月25号).
- TuHura Biosciences and Kintara Therapeutics have merged (公布2024十月20号)..
生物技术 行业的其他推荐联系人
消息
Akebia Therapeutics 的最新新闻稿
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Akebia Therapeutics
- Akebia Therapeutics to Report Second Quarter Financial Results | Akebia Therapeutics
- Akebia Therapeutics Regaining Rights to Vadadustat in the United States, Europe, China and Access Consortium Countries upon Termination of Collaboration and License Agreements with Otsuka | Akebia Therapeutics
- Akebia Therapeutics to Present at Jefferies Healthcare Conference | Akebia Therapeutics
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Akebia Therapeutics
- Akebia Therapeutics to Present at H.C. Wainwright Global Investment Conference | Akebia Therapeutics
- Akebia Therapeutics to Report First Quarter Financial Results | Akebia Therapeutics
- Akebia to Present Global Phase 3 Vadadustat Data at American Society of Nephrology Kidney Week 2020 Reimagined | Akebia Therapeutics
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Akebia Therapeutics
- Akebia Therapeutics Announces September 2020 Investor Conference Schedule | Akebia Therapeutics
- View more press releases Close
通过电子邮件
